Mina, Lida

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 2,175

Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma

Kakadia, S., Yarlagadda, N., Awad, R., Kundranda, M., Niu, J., Naraev, B., Mina, L., Dragovich, T., Gimbel, M., & Mahmoud, F. (2018) · OncoTargets and Therapy

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 277

Acceptance and commitment therapy for symptom interference in metastatic breast cancer patients: a pilot randomized trial

Mosher, C. E., Secinti, E., Li, R., Hirsh, A. T., Bricker, J., Miller, K. D., Schneider, B., Storniolo, A. M., Mina, L., Newton, E. V., et al. (2018) · Supportive Care in Cancer

Cancer survivorship and careMindfulness and Compassion Interventions

Cited by 95

Symptom experiences in metastatic breast cancer patients: relationships to activity engagement, value-based living, and psychological inflexibility

Mosher, C. E., Tometich, D. B., Hirsh, A., Rand, K. L., Johns, S. A., Matthias, M. S., Outcalt, S. D., Bricker, J., Schneider, B., Mina, L., et al. (2017) · Psycho-Oncology

Cancer survivorship and careMindfulness and Compassion Interventions

Cited by 34

Relations of Mindfulness and Illness Acceptance With Psychosocial Functioning in Patients With Metastatic Breast Cancer and Caregivers.

Chinh, K., Secinti, E., Johns, S., Hirsh, A., Miller, K., Schneider, B., Storniolo, A. M., Mina, L., Newton, E., Champion, V., et al. (2020) · Oncology Nursing Forum

Mindfulness and Compassion InterventionsCancer survivorship and care

Cited by 17

Abstract CT071: Talazoparib (TALA) in germline BRCA1/2 (g BRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): Final overall survival (OS) results from randomized Phase 3 EMBRACA trial

Litton, J. K., Hurvitz, S. A., Mina, L. A., Rugo, H. S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., et al. (2020) · Cancer Research

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 10